Glucose Health, Inc.
GLUC · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.46 | 0.32 | -0.21 | 1.30 |
| FCF Yield | -23.18% | -5.12% | -4.55% | -0.34% |
| EV / EBITDA | -7.37 | -10.80 | -14.72 | -60.99 |
| Quality | ||||
| ROIC | -181.00% | -163.72% | -97.41% | -29.32% |
| Gross Margin | 19.67% | 40.35% | 42.58% | 43.00% |
| Cash Conversion Ratio | 1.44 | 0.58 | 1.45 | 0.21 |
| Growth | ||||
| Revenue 3-Year CAGR | -28.99% | -17.54% | 30.67% | 48.50% |
| Free Cash Flow Growth | -94.25% | 37.35% | -435.00% | -0.70% |
| Safety | ||||
| Net Debt / EBITDA | -0.68 | 0.48 | 0.48 | 2.24 |
| Interest Coverage | -32.70 | 0.00 | 0.00 | -120.69 |
| Efficiency | ||||
| Inventory Turnover | 1.24 | 1.85 | 2.03 | 2.03 |
| Cash Conversion Cycle | 290.37 | 115.87 | 175.55 | 184.69 |